Javascript must be enabled to continue!
P46 Takotsubo cardiomyopathy in a GPA patient receiving rituximab therapy
View through CrossRef
Abstract
Background
Cardiac involvement in GPA is quite rare. Patients with GPA are two times more likely to die of cardiovascular complications as compared to the general population due to accelerated atherosclerosis. Cardiac involvement in GPA is secondary to necrotising vasculitis with granulomatous infiltrates, usually resulting in coronary artery thrombosis. We present a case of Takotsubo cardiomyopathy in a patient of GPA treated with rituximab. There has previously only been one case report of a patient on rituximab therapy developing Takotsubo cardiomyopathy.
Methods
This 67-year-old woman was diagnosed with GPA in January 2018 when she presented with a necrotic lung lesion along with nasal crusting and leg ulcers. Her ANCA was 102 i.u./ml at the time. We treated with cyclophosphamide and azathioprine to good effect. Then she had a relapse six months later and presented to the hospital with stridor due to subglottic stenosis. At this point we switched to rituximab and methotrexate to induce remission, her ANCA titres settled to 3.4 i.u./ml at this point. After her second cycle of rituximab, she presented to the hospital with shortness of breath, chest pain and stridor in November 2018.
Results
At her presentation with chest pain in November 2018, an ECG was performed, which showed an incomplete LBBB with ST elevation in anterior leads with a troponin level of 550ng/ml. A repeat ECG after 2 hours, showed ST elevations in anterolateral leads with a troponin level of 1259ng/ml. We treated this as an acute myocardial infarction. An echocardiogram was obtained, which was remarkable in that it showed no new regional wall motion abnormalities. A subsequent coronary angiogram confirmed that there was no coronary artery disease raising the possibility of Takotsubo cardiomyopathy.
Conclusion
Rituximab is implicated in cardiac arrhythmia and coronary vasospasm during the infusion, reduction in LVEF, non-ischaemic cardiomyopathy, cardiogenic shock after. Our patient had a myocardial infarction with normal coronaries, and she was going through a very emotionally stressful period with her husband’s illness at the time of her presentation, which makes Takatsubo cardiomyopathy a very likely diagnosis. There are few case reports in the literature and, clinicians should be aware of this rare complication.
Disclosures
S.P. Jayanti None. S. Nair None. D. Makkuni None.
Title: P46 Takotsubo cardiomyopathy in a GPA patient receiving rituximab therapy
Description:
Abstract
Background
Cardiac involvement in GPA is quite rare.
Patients with GPA are two times more likely to die of cardiovascular complications as compared to the general population due to accelerated atherosclerosis.
Cardiac involvement in GPA is secondary to necrotising vasculitis with granulomatous infiltrates, usually resulting in coronary artery thrombosis.
We present a case of Takotsubo cardiomyopathy in a patient of GPA treated with rituximab.
There has previously only been one case report of a patient on rituximab therapy developing Takotsubo cardiomyopathy.
Methods
This 67-year-old woman was diagnosed with GPA in January 2018 when she presented with a necrotic lung lesion along with nasal crusting and leg ulcers.
Her ANCA was 102 i.
u.
/ml at the time.
We treated with cyclophosphamide and azathioprine to good effect.
Then she had a relapse six months later and presented to the hospital with stridor due to subglottic stenosis.
At this point we switched to rituximab and methotrexate to induce remission, her ANCA titres settled to 3.
4 i.
u.
/ml at this point.
After her second cycle of rituximab, she presented to the hospital with shortness of breath, chest pain and stridor in November 2018.
Results
At her presentation with chest pain in November 2018, an ECG was performed, which showed an incomplete LBBB with ST elevation in anterior leads with a troponin level of 550ng/ml.
A repeat ECG after 2 hours, showed ST elevations in anterolateral leads with a troponin level of 1259ng/ml.
We treated this as an acute myocardial infarction.
An echocardiogram was obtained, which was remarkable in that it showed no new regional wall motion abnormalities.
A subsequent coronary angiogram confirmed that there was no coronary artery disease raising the possibility of Takotsubo cardiomyopathy.
Conclusion
Rituximab is implicated in cardiac arrhythmia and coronary vasospasm during the infusion, reduction in LVEF, non-ischaemic cardiomyopathy, cardiogenic shock after.
Our patient had a myocardial infarction with normal coronaries, and she was going through a very emotionally stressful period with her husband’s illness at the time of her presentation, which makes Takatsubo cardiomyopathy a very likely diagnosis.
There are few case reports in the literature and, clinicians should be aware of this rare complication.
Disclosures
S.
P.
Jayanti None.
S.
Nair None.
D.
Makkuni None.
Related Results
Could rituximab be a silver lining in refractory bone marrow fibrosis caused by lupus?
Could rituximab be a silver lining in refractory bone marrow fibrosis caused by lupus?
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that can present with a variety of clinical manifestations, ranging from mild skin involvement to multisystemic ...
Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash
Abstract
This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
Rituximab Use in Children - A Single Center Experience.
Rituximab Use in Children - A Single Center Experience.
Abstract
Treatment of children with chronic refractory ITP often results in significant morbidity and current therapies induce remission in fewer than half of childr...
Rituximab Induces Long Lasting Clinical and Serological Remission in Refractory Antiphospholipid Syndrome (APS) and Related Disorders.
Rituximab Induces Long Lasting Clinical and Serological Remission in Refractory Antiphospholipid Syndrome (APS) and Related Disorders.
Abstract
INTRODUCTION. Rituximab, a chimeric monoclonal antibody against CD20 expressed on B cells, has been approved for the treatment of B cell neoplasms. Recently...
Abstract 1487: Gene expression and linkage analysis implicates CBLB as a mediator of rituximab resistance
Abstract 1487: Gene expression and linkage analysis implicates CBLB as a mediator of rituximab resistance
Abstract
Drug resistance remains one of the largest challenges in the curative treatment of cancer. We investigated the problem of monoclonal antibody resistance in ...
GA101-Coated Target Cells Are More Effective Than Rituximab-Coated Target Cells at Activating NK Cells When Complement Is Present.
GA101-Coated Target Cells Are More Effective Than Rituximab-Coated Target Cells at Activating NK Cells When Complement Is Present.
Abstract
Abstract 2707
Poster Board II-683
Rituximab has had a major impact on the treatment of B...
278 Cardiac involvement in a 23 years old patient with granulomatosis with polyangiitis (GPA)
278 Cardiac involvement in a 23 years old patient with granulomatosis with polyangiitis (GPA)
Abstract
Aims
Granulomatosis with polyangiitis (GPA) is a systemic necrotizing vasculitis, which could potentially affect any or...
Takotsubo Cardiomyopathy: A Brief Review
Takotsubo Cardiomyopathy: A Brief Review
Takotsubo cardiomyopathy is a reversible cardiomyopathy with a unique morphological feature of the left ventricle characterized by an apical ballooning appearance known for approxi...

